Recent Finacing
Recent Raise
Olema Oncology is a clinical-stage biopharmaceutical company developing OP-1250, a CERAN/SERD evaluated in Phase 1/2 trials for ER-positive, HER2-negative recurrent or metastatic breast cancer, including combination studies.
